14/09/2021 - Desang Diabetes Services

Eli Lilly’s Lyumjev receives FDA approval

14/09/2021 No Comments

Eli Lilly has received FDA approval and expanded labelling for its Lyumjev rapid-acting insulin. Lyumjev is a novel formulation of insulin lispro for speeding up

Fractyl Health trialling Revita DMR

14/09/2021 No Comments

Fractyl Health has activated the 10th clinical site in its REVITA-T2Di trial in the United States and Europe. The trial is a prospective, randomised, double-blind,

Eli Lilly’s Lyumjev receives FDA approval

Fractyl Health trialling Revita DMR

Latest tweets

Twitter: desangsue

Recent posts

Type 2 remission over ‘cure’

Dexcom launches Time in Range campaign

FreeStyle LibreLink app users spend more Time in Range